Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR ‐T Cells Against B‐Cell Lymphoma
Cancer Science · 2025
DOI: 10.1111/cas.70123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Wenjing Luo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Macrophages, Triazoles, Hydrazines, Antigens, CD19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
CD19 chimeric antigen receptor (CAR)‐T cell therapy has achieved high response rates in patients with B‐cell lymphoma. However, treatment failure and relapse can be attributable to CAR‐T cell dysfunction and the immunosuppression of the tumor microenvironment. Combination therapy emerges as a solution strategy, and selinexor might be a potential candidate. In this study, we first established the ex vivo tumor microenvironment model by coculturing tumor cells and macrophages, followed by coculture with CAR‐T cells, and identified that selinexor decreased CAR‐T cell exhaustion and enhanced its cytotoxicity. Moreover, selinexor upregulated NGFR expression and boosted CAR‐T cell proliferation. The ex vivo and in vivo results showed that selinexor prevented macrophages from polarizing to M2 populations. In the xenograft animal model, the sequential use of selinexor and CAR‐T cells significantly reduced the tumor burden compared with selinexor or CAR‐T cell monotherapies. In summary, our findings suggest that selinexor mitigates the immunosuppression of macrophages and improves CAR‐T cell functionality, and the combination of selinexor and CAR‐T cells may be a promising therapeutic strategy for B‐cell lymphoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, Hubei, China.
- Key Laboratory of Biological Targeted Therapy (Huazhong University of Science and Technology), Ministry of Education, Wuhan, Hubei, China.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Luo, W., Xu, J., Li, C., Tang, L., Li, Y., Wang, X., Wu, Z., Zhang, Y., Mei, H., & Hu, Y. (2025). Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR ‐T Cells Against B‐Cell Lymphoma. Cancer Science. https://doi.org/10.1111/cas.70123
Vancouver
Luo W, Xu J, Li C, Tang L, Li Y, Wang X, et al. Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR ‐T Cells Against B‐Cell Lymphoma. Cancer Science. 2025. doi:10.1111/cas.70123
BibTeX
@article{Luo2025,
author = {Luo, Wenjing and Xu, Jia and Li, Chenggong and Tang, Lu and Li, Yingying and Wang, Xindi and Wu, Zhuolin and Zhang, Yinqiang and Mei, Heng and Hu, Yu},
title = {Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR ‐T Cells Against B‐Cell Lymphoma},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70123}
}
EUVIMED